A Clinical Study of Tranilast in the Treatment of Sarcoidosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

EARLY_PHASE1

Total Enrollment

56 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-31

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

56 patients with sarcoidosis will be selected to receive treatment of tranilast.The investigators can analyse the changes in the thickness and area of skin lesions before and after treatment as well as other involved organs nodule size changes to determine the efficacy and safety of drugs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

SARCOTHAL. Thalidomide in Skin Sarcoidosis

NCT00305552

Sarcoidosis

COMPLETED PHASE3

A Phase 2 Study With CC-220 in Skin Sarcoidosis

NCT02192489

Sarcoidosis

WITHDRAWN PHASE2

Sirolimus in Cutaneous Sarcoidosis

NCT05458492

Sarcoidosis Cutaneous Sarcoidosis

NOT_YET_RECRUITING PHASE2

Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma

NCT00070590

Pulmonary Fibrosis Scleroderma, Systemic

COMPLETED PHASE2/PHASE3

Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement

NCT00573326

Systemic Sclerosis

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

56 patients with sarcoidosis will be selected. After the signing of the informed consent ,participants will be collected the initial lesions photos, the size of the lump by ultrasound, the forced vital capacity(FVC), and chemical examinations including blood routine examination, routine urine test, liver function, renal function. During tranilast treatment (0.1g each time, three times a day) , participants need regular follow-up (1 per month) including liver and kidney function, blood glucose level monitoring, every three months to retest ultrasound and the forced vital capacity(FVC). With 3 month as a time point, participants were observed for four points(one point if only skin invasion ).After the experiment, the experimental data will be arranged and the data will be statistically processed (t test) to determine whether it is meaningful.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcoidosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tranilast

Group Type EXPERIMENTAL

Tranilast

Intervention Type DRUG

Subjects will be treated with tranilast

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tranilast

Subjects will be treated with tranilast

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* (1)patients with diagnosed sarcoidosis, the skin pathology showed non necrotic granuloma and negative staining of fungi and atypical mycobacterium; (2)No corticosteroids and immunosuppressants were used for nearly 1 months.